Aurobindo Pharma Q2 results: Net profit drops 41% to Rs 409 crore
Aurobindo Pharma Vice-Chairman and Managing Director K Nithyananda Reddy said the company’s second quarter performance was subdued, mainly due to macro-environment factors and higher competitive intensity for some products in the US.
Billions of dollars lost! How Twitter Blue troubled investors on Wall Street
Similarly, Lockheed Martin shares also ended 5.5% down after an imposter said the company will begin halting all weapon sales to Saudi Arabia, Israel and the US until further investigation into their record of human rights abuses.
Philippe Jorion’s effective risk management tips for huge returns
Philippe Jorion is Professor of Finance at the Graduate School of Management at the University of California, Irvine. He has also taught at Columbia University, Northwestern University, the University of Chicago, and the University of British Columbia. He holds an MBA and a Phd from the University of Chicago and a degree in engineering from […]
ETMarkets Management Talk | Demand in US, Europe higher than 2019: RateGain CFO Tanmaya Das
“We believe our ability to drive interoperability between our products will be the key growth driver for RateGain over the next two years.”
Patanjali Foods Q2 Results: Profit drops 31.6% YoY to Rs 112.28 cr, revenue jumps 42%
The company, earlier known as Ruchi Soya, said the quarter witnessed multiple headwinds in the edible oil segment
Bank Nifty likely to stage breakout if it can keep its head above 42,000 levels
Volatility continued to slide; India VIX came off by another 7.98% to 14.40; this is one of the lowest levels seen this year. The coming week is likely to see a stable start
HNI investors made up to 9% return last month using PMS funds
Beating not just benchmark indices but also star fund managers, an 8-month-old PMS scheme betting on smallcaps turned out to be the star performer, shows data pulled from PMS Bazaar. With a return of 9.09%, Hem Securities’ India Rising SME Stars fund topped the charts of PMS funds.
Siddhartha Khemka hand picks Sun Pharma, Axis Bank which could give 14-20% return in a year
Excluding metals and O&G, Nifty posted a solid 25% earnings growth vs. expectations of 20%, fuelled by BFSI and autos. Along with metals and O&G, the cement sector also dragged 2QFY23 earnings
Bored of fixed deposits? 7 PSU stocks that announced dividend this week
Even though conservative investments such as fixed deposits have begun to fetch a higher rate with the interest rate in the country trending higher, investors often hunt for investment propositions that can amplify their income stream and that too on a consistent basis. So, here are some of the high dividend yield stocks that have […]
Sun Pharma, Lupin and Torrent will continue to rally: Apurva Sheth, Samco Securities
“Bank Nifty will sustain its bullish momentum. The banking index on the weekly timeframe has witnessed a bullish breakout above its horizontal trend line, which is placed at 41,800 levels. “